B. Riley Predicts Weaker Earnings for Trevi Therapeutics
Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) – Equities research analysts at B. Riley dropped their Q2 2025 earnings per share (EPS) estimates for Trevi Therapeutics in a research note issued on Wednesday, March 19th. B. Riley analyst M. Mamtani now expects that the company will earn ($0.16) per share for the quarter, down from […]
Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) – Equities research analysts at B. Riley dropped their Q2 2025 earnings per share (EPS) estimates for Trevi Therapeutics in a research note issued on Wednesday, March 19th. B. Riley analyst M. Mamtani now expects that the company will earn ($0.16) per share for the quarter, down from […]
